^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SIM0237

    i
    Other names: SIM0237, SIM 0237, SIM-0237, SIM237
    Associations

    News

    Trials
    Company:
    Simcere
    Drug class:
    PD-L1 inhibitor, IL-15 stimulant
    Related drugs:
    Associations

    News

    Trials
    11ms
    A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC (clinicaltrials.gov)
    P1, N=152, Recruiting, Jiangsu Simcere Pharmaceutical Co., Ltd. | N=108 --> 152
    Enrollment change
    |
    SIM0237
    12ms
    A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants with Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=192, Terminated, Jiangsu Simcere Pharmaceutical Co., Ltd. | Trial completion date: Jan 2026 --> May 2024 | Recruiting --> Terminated | Trial primary completion date: Apr 2025 --> May 2024; An internal business decision, not based on safety or regulatory considerations.
    Trial completion date • Trial termination • Trial primary completion date • Metastases
    |
    SIM0237
    almost2years
    A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination With BCG in NMIBC (clinicaltrials.gov)
    P1, N=108, Recruiting, Jiangsu Simcere Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    SIM0237
    almost2years
    A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination With BCG in NMIBC (clinicaltrials.gov)
    P1, N=108, Not yet recruiting, Jiangsu Simcere Pharmaceutical Co., Ltd.
    New P1 trial • Combination therapy
    |
    SIM0237
    over2years
    A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1; N=192; Recruiting; Sponsor:Jiangsu Simcere Pharmaceutical Co., Ltd.
    New P1 trial • Metastases
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    |
    SIM0237